Induction therapy in pancreas transplantation

Transplant International

Volumn 26, Issue 7, 2013, Pages 704-714

  Niederhaus, Silke V ^a   Kaufman, Dixon B ^b   Odorico, Jon S ^b  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

graft survival; immunosuppression; induction therapy; pancreas transplantation; rejection

Indexed keywords

ALEMTUZUMAB; ANTIHISTAMINIC AGENT; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; OKT 3; PARACETAMOL; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; APNEA; ARTHRALGIA; ASEPTIC MENINGITIS; BACKACHE; BRONCHOSPASM; CHILL; COMPARATIVE STUDY; CYTOKINE RELEASE SYNDROME; DELAYED GRAFT FUNCTION; DIARRHEA; DRUG HALF LIFE; DYSPNEA; FEVER; FLANK PAIN; GRAFT RECIPIENT; GRAFT SURVIVAL; HEADACHE; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY ALLOGRAFT; KIDNEY GRAFT; LEUKOPENIA; LUNG EDEMA; LYMPHOMA; MAINTENANCE THERAPY; MALAISE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; OPPORTUNISTIC INFECTION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REGISTER; REVIEW; RIGOR; RISK FACTOR; SEIZURE; SERUM SICKNESS; SINGLE DRUG DOSE; STEROID THERAPY; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MUROMONAB-CD3; PANCREAS TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS;

EID: 84879015540     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12122     Document Type: Review

References (34)

1. Gruessner AC,. 2011 Update on pancreas transplantation: comprehensive trend analysis of 25,000 cases followed up over the course of twenty-four years at the International Pancreas Transplant Registry (IPTR). Rev Diabet Stud 2011; 8: 6.
2. OPTN & SRTR Annual Data Report 2011. Published at http://srtr.transplant.hrsa.gov/annual-reports/2011/pdf/2011-SRTR-ADR.pdf, accessed March 17, 2013.
3. Gruessner RWG, Sutherland DER,. Transplantation of the pancreas. Chapter 10 Immunosuppression in pancreas transplantation, Section 1 induction therapy, 1st edn. Springer-Verlag New York, Inc, 2004: 267.
4. Sollinger HW, Stratta RJ, D'Alessandro AM, et al,. Experience with simultaneous pancreas-kidney transplantation. Ann Surg 1988; 208: 475.
5. Sutherland DER, Dunn DL, Goetz FC, et al,. A 10-year experience with 290 pancreas transplants at a single institution. Ann Surg 1989; 209: 274.
6. Bunn D, Lea CK, Bevan DJ, et al,. The pharmacokinetics of antithymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol 1996; 1: 29.
7. Forsythe J,. ATG dosing: daily or less frequently? Graft 1999; 2 (suppl): S10.
8. Goggins WC, Pascual MA, Powelson JA, et al,. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
9. Knechtle SJ, Pirsch JD, Fechner JH Jr, et al,. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
10. Stratta RJ, Alloway RR, Hodge E, Lo A,. A Multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis. Transpl Proc 2002; 34: 1903.
11. Stratta RJ, Alloway RR, Lo A, Hodge EE,. A prospective, randomized, multicenter study evaluating the safety and efficacy of two dosing regimens of daclizumab compared to no antibody induction in simultaneous kidney-pancreas transplantation: results at 3 years. Transpl Proc 2005; 37: 3531.
12. Kaufman DB, Burke GW III, Bruce DS, et al,. Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation. Am J Transplant 2003; 3: 855.
13. Farney AC, Doares W, Rogers J, et al,. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810.
14. Farney A, Sundberg A, Moore P, et al,. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008; 22: 41.
15. Lo A, Stratta RJ, Alloway RR, et al,. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. Transpl Proc 2001; 33: 1701.
16. Desai DM, Scandling JD, Knoppel C, Dafoe DC, Alfrey EJ,. Low-dose OKT3 treatment for rejection/induction in kidney and kidney-pancreas transplantation. Transpl Proc 1998; 30: 1552.
17. Cantarovich D, Karam G, Giral-Classe M, et al,. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation. Kidney Int 1998; 54: 1351.
18. Boesmueller C, Oellinger R, Sieb M, et al,. Tacrolimus monotherapy following alemtuzumab induction in combined kidney-pancreas transplantation: results of a prospective randomized trial. Ann Transplant 2012; 17: 45.
19. Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ,. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation. Transpl Proc 2005; 37: 1294.
20. Pascual J, Pirsch JD, Odorico JS, et al,. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation 2009; 87: 125.
21. Reddy KS, Devarapalli Y, Mazur M, et al,. Alemtuzumab with rapid steroid taper in simultaneous kidney and pancreas transplantation: comparison to induction with antithymocyte globulin. Transpl Proc 2010; 42: 2006.
22. Magliocca JF, Odorico JS, Pirsch JD, et al,. A comparison of alemtuzumab with basiliximab induction in simultaneous pancreas-kidney transplantation. AJT 2008; 8: 1702.
23. Kaufman DB, Leventhal JR, Gallon LG, Parker MA,. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction-long-term results. AJT 2006; 6: 331.
24. Burke GW, Ciancio G, Alejandro R, et al,. Use of tacrolimus and mycophenolate mofetil for pancreas-kidney transplantation with or without OKT3 induction. Transpl Proc 1998; 30: 1544.
25. Bazerbachi F, Selzner M, Boehnert MU, et al,. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome. Transplantation 2011; 92: 1039.
26. Humar A, Limaye AP, Blumberg EA, et al,. Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study. Transplantation 2010; 90: 1427.
27. Corry RJ, Egidi MF, Shapiro R, et al,. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. Transpl Proc 1998; 30: 521. (Pubitemid 28207279)
28. Knight RJ, Kerman RH, McKissick E, et al,. Selective corticosteroid and calcineurin inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy. Clin Transplant 2008; 22: 645.
29. Tan M, Cantarovich M, Mangel R, Paraskevas S, Fortier M, Metrakos P,. Reduced dose thymoglobulin, tacrolimus, and mycophenolate mofetil results in excellent solitary pancreas transplant outcomes. Clin Transplant 2002; 16: 414.
30. Bonatti H, Berger N, Kafka R, et al,. Experience with ATG short course high dose induction therapy in a series of 112 enteric drained pancreatic transplants. Ann Transplant 2002; 7: 22.
31. Dawson KL, Patel SJ, Xu J, Knight RJ, Gaber O,. Effect of immunosuppression for first kidney or kidney/pancreas transplant on sensitization at the time of second transplant. Transplantation 2011; 91: 751.
32. Zhang R, Florman S, Devidoss S, et al,. The long-term survival of simultaneous pancreas and kidney transplant with basiliximab induction therapy. Clin Transplant 2007; 21: 583.
33. Muthusamy ASR, Vaidya AC, Sinha S, Roy D, Elker DE, Friend PJ,. Alemtuzumab induction and steroid-free maintenance immunosuppression in pancreas transplantation. AJT 2008; 8: 2126.
34. Uemura T, Ramprasad V, Matsushima K, et al,. Single dose of alemtuzumab induction with steroid-free maintenance immunosuppression in pancreas transplantation. Transplantation 2011; 92: 678.